<DOC>
	<DOCNO>NCT01640782</DOCNO>
	<brief_summary>Open label , randomise , multicenter , superiority study efficacy . Patients histologically proven adenocarcinoma stomach gastroesophageal junction without gross microscopic evidence residual disease surgery curative intent fulfil inclusion/exclusion criterion eligible study .</brief_summary>
	<brief_title>Intergroup Trial Adjuvant Chemotherapy Adenocarcinoma Stomach</brief_title>
	<detailed_description>Open label , randomise , multicenter , superiority study efficacy . Patients histologically proven adenocarcinoma stomach gastroesophageal junction without gross microscopic evidence residual disease surgery curative intent fulfil inclusion/exclusion criterion eligible study . Allocation treatment do centrally use randomisation scheme stratify center nodal involvement ( N- vs. N+ ) . Access random system allow phone via web . All include patient group receive fixed period 18 week treatment unless unacceptable toxicity disease relapse treatment . After cessation therapy , patient follow-up period receive treatment . After relapse chemotherapy leave investigator 's judgement . When last patient randomise , follow-up truncated achievement require number event . Time progression time death main study outcome . During course trial , independent Data Safety Monitoring Board ( DSMB ) advise Steering Committee efficacy and/or safety aspect study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically proven adenocarcinoma stomach gastroesophageal junction without gross microscopic evidence residual disease surgery curative intent ; Subtotal total gastrectomy least D1 dissection ; Gastroesophageal junction adenocarcinoma extend stomach center lie 2 5 cm anatomic esophagogastric junction ; Patients nodal involvement ( pN+ ) patient without nodal involvement ( pN0 ) pT2b34 . It recommend examine least 15 lymph node ; Age 18 75 year ; ECOG performance status 01 ; No previous chemotherapy and/or radiotherapy ; Complete staging procedure within 3 month prior randomization ; Laboratory requirement ( within 8 day prior randomization ) : Haematology ( Neutrophils &gt; 2.0 x 109 /L , Platelet &gt; 100 x 109 /L , Hemoglobin &gt; 10g/dL ) ; Hepatic function ( Total bilirubin &lt; 1 UNL , ASAT ( SGOT ) ALAT ( SGPT ) &lt; 2.5xUNL , Alkaline phosphatase &lt; 2.5xUNL . Patients ASAT ALAT &gt; 1.5xUNL associated alkaline phosphatase &gt; 2.5XUNL eligible . ) Renal function ( Creatinine &lt; 1.5 UNL . In presence borderline value , calculate creatinine clearance accord CockroftGault formula , 60 ML/min . Recovery acute effect surgery . The first infusion study chemotherapy administer 3 8 week surgery treatment ; Written inform consent sign date randomization procedure , include expect cooperation patient treatment followup , must obtain document accord local regulatory requirement . Nonradical surgery assess microscopically ( tumorfree margin resection , positive biopsy peritoneal suspicious lesion ) ; Synchronous metastasis , even curatively resect ; Pregnant lactating patient ; patient reproductive potential must implement adequate contraceptive measure ; Prior concurrent history : positive HIV serology , chronic diarrhoea , chronic bowel inflammation subobstruction , neoplasm gastric cancer , except : curatively treat nonmelanoma skin cancer , situ carcinoma cervix , previous history myocardial infarction within 1 year study entry , hypersensitivity reaction polysorbate 80 ; Presence systemic disease limit drug administration influence patient survival : uncontrolled hypertension , highrisk uncontrolled arrhythmia , unstable angina pectoris ; Symptomatic peripheral neuropathy , alter hearing &gt; 2 grade NCICCTG criterion ; Active uncontrolled infection . Definite contraindication use corticosteroid : unstable diabetes mellitus , active peptic ulcer ; Concurrent administration : corticosteroid equivalent except use prophylactic medication regimen , treatment acute hypersensitivity reaction unless chronic treatment ( initiate &gt; 6 month prior study entry ) low dos ( &lt; 20mg methylprednisolone equivalent ) ; experimental drug investigation : concurrent treatment anticancer therapy , growth factor preventive intent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma gastroesophageal junction</keyword>
</DOC>